IP Library › Granted Patent US 8,546,431
Granted Patent B2
US 8,546,431 · App. 13/663,622 · Granted Oct 1, 2013

5-lipoxygenase-activating protein (FLAP) inhibitors

Inventors: John H. Hutchinson (La Jolla, CA); Petpiboon Peppi Prasit (Rancho Santa Fe, CA); Mark Moran (Orinda, CA); Jillian F. Evans (San Diego, CA); Yiwei Li (Lower Gwynedd, PA); Jeannie M. Arruda (San Diego, CA)
Assignee: Panmira Pharmaceuticals, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,431
App. No.
13/663,622
Granted
Oct 1, 2013
Kind
B2
Abstract

A method for treating a human comprises administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need.

Claims (12)

1. A method for treating a respiratory disease consisting of asthma, chronic obstructive pulmonary disease, or rhinitis in a human comprising administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need.

2. The method according to claim 1 , wherein the respiratory disease is asthma.

3. The method according to claim 1 , wherein the respiratory disease is chronic obstructive pulmonary disease.

4. The method according to claim 1 , wherein the respiratory disease is rhinitis.

5. The method according to claim 1 , wherein 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid is present in form of a sodium salt.

6. The method according to claim 5 , wherein the respiratory disease is asthma.

7. The method according to claim 5 , wherein the respiratory disease is chronic obstructive pulmonary disease.

8. The method according to claim 5 , wherein the respiratory disease is rhinitis.

9. A method for treating a respiratory disease consisting of asthma, chronic obstructive pulmonary disease, or rhinitis in a human comprising administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need.

10. The method according to claim 9 , wherein the respiratory disease is asthma.

11. The method according to claim 9 , wherein the respiratory disease is chronic obstructive pulmonary disease.

12. The method according to claim 9 , wherein the respiratory disease is rhinitis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2019
From: PANMIRA PHARMACEUTICALS, LLC
To: AUTOIMMUNE PHARMA LLC
Reel/Frame 048310/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: AMIRA PHARMACEUTICALS, INC.
To: PANMIRA PHARMACEUTICALS, LLC
Reel/Frame 030826/0871 →
Continuity (2)
Division 12089707 · Oct 1, 2008
Related Publication 20130102636A1 · Apr 25, 2013